Qsemble Capital Management LP Has $418,000 Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Qsemble Capital Management LP cut its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 14.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 22,693 shares of the company’s stock after selling 3,804 shares during the quarter. Qsemble Capital Management LP’s holdings in Hims & Hers Health were worth $418,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Quest Partners LLC grew its position in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the period. CWM LLC grew its position in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the period. Arizona State Retirement System boosted its position in Hims & Hers Health by 3.0% during the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after acquiring an additional 1,173 shares during the last quarter. Victory Capital Management Inc. boosted its position in Hims & Hers Health by 6.6% during the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after acquiring an additional 1,212 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Down 1.1 %

Shares of Hims & Hers Health stock opened at $30.35 on Thursday. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02. The business’s 50 day moving average is $21.14 and its 200-day moving average is $19.57. The stock has a market cap of $6.63 billion, a P/E ratio of 68.98 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the business earned ($0.04) EPS. The firm’s revenue for the quarter was up 77.1% on a year-over-year basis. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on HIMS. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price target for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Needham & Company LLC began coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Finally, Canaccord Genuity Group upped their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.71.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,345 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the sale, the insider now owns 159,796 shares in the company, valued at approximately $2,341,011.40. This represents a 1.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Chi sold 7,500 shares of the stock in a transaction on Monday, October 21st. The shares were sold at an average price of $22.20, for a total value of $166,500.00. Following the completion of the sale, the insider now owns 193,980 shares in the company, valued at approximately $4,306,356. This trade represents a 3.72 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,153,519 shares of company stock worth $24,486,721. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.